Mirtazapine reduces adipocyte hypertrophy and increases glucose transporter expression in obese mice

Ching Feng Wu, Po Hsun Hou, Frank Chiahung Mao, Yao Chi Su, Ching Yang Wu, Wei Cheng Yang, Chen Si Lin, Hsiao Pei Tsai, Huei Jyuan Liao, Geng Ruei Chang*


研究成果: 期刊稿件文章同行評審

11 引文 斯高帕斯(Scopus)


Metabolic syndrome is known to engender type 2 diabetes as well as some cardiac, cerebrovascular, and kidney diseases. Mirtazapine—an atypical second-generation antipsychotic drug with less severe side effects than atypical first-generation antipsychotics—may have positive effects on blood glucose levels and obesity. In our executed study, we treated male high-fat diet (HFD)-fed C57BL/6J mice with mirtazapine (10 mg/kg/day mirtazapine) for 4 weeks to understand its antiobesity effects. We noted these mice to exhibit lower insulin levels, daily food efficiency, body weight, serum triglyceride levels, aspartate aminotransferase levels, liver and epididymal fat pad weight, and fatty acid regulation marker expression when compared with their counterparts (i.e., HFD-fed control mice). Furthermore, we determined a considerable drop in fatty liver scores and mean fat cell size in the epididymal white adipose tissue in the treated mice, corresponding to AMP-activated protein kinase expression activation. Notably, the treated mice showed lower glucose tolerance and blood glucose levels, but higher glucose transporter 4 expression. Overall, the aforementioned findings signify that mirtazapine could reduce lipid accumulation and thus prevent HFD-induced increase in body weight. In conclusion, mirtazapine may be useful in body weight control and antihyperglycemia therapy.

頁(從 - 到)1-17
出版狀態已出版 - 08 2020


Publisher Copyright:
© 2020 by the authors. Licensee MDPI, Basel, Switzerland.


深入研究「Mirtazapine reduces adipocyte hypertrophy and increases glucose transporter expression in obese mice」主題。共同形成了獨特的指紋。